SYNAPTOGENIX INC (SNPX) Stock Price, Quote, News and Overview
NASDAQ:SNPX - Nasdaq - US87167T3005 - Common Stock - Currency: USD
SNPX Quote, Performance and Key Statistics
2.4098
+0.01 (+0.41%)
The current stock price of SNPX is 2.4098 USD. In the past month the price increased by 12.35%. In the past year, price decreased by -47.27%.
SNPX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.97 | 326.55B | ||
| AMGN | AMGEN INC | 12.81 | 142.94B | ||
| GILD | GILEAD SCIENCES INC | 12.52 | 120.65B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 109.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.91 | 56.98B | ||
| ARGX | ARGENX SE - ADR | 93.64 | 33.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.67B | ||
| ONC | BEIGENE LTD-ADR | 5.79 | 25.01B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.30B | ||
| NTRA | NATERA INC | N/A | 20.66B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
| BIIB | BIOGEN INC | 7.47 | 17.32B |
Related stock screener links
About SNPX
Company Profile
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2020-12-07. The firm is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The firm is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
Company Info
SYNAPTOGENIX INC
1185 Avenue Of The Americas, 3Rd Floor
New York City NEW YORK US
CEO: Alan J. Tuchman
Employees: 4
Phone: 19732420005
SYNAPTOGENIX INC / SNPX FAQ
What is the stock price of SYNAPTOGENIX INC today?
The current stock price of SNPX is 2.4098 USD. The price increased by 0.41% in the last trading session.
What is the ticker symbol for SYNAPTOGENIX INC stock?
The exchange symbol of SYNAPTOGENIX INC is SNPX and it is listed on the Nasdaq exchange.
On which exchange is SNPX stock listed?
SNPX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SYNAPTOGENIX INC stock?
7 analysts have analysed SNPX and the average price target is 14.28 USD. This implies a price increase of 492.58% is expected in the next year compared to the current price of 2.4098. Check the SYNAPTOGENIX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SYNAPTOGENIX INC worth?
SYNAPTOGENIX INC (SNPX) has a market capitalization of 3.35M USD. This makes SNPX a Nano Cap stock.
How many employees does SYNAPTOGENIX INC have?
SYNAPTOGENIX INC (SNPX) currently has 4 employees.
What are the support and resistance levels for SYNAPTOGENIX INC (SNPX) stock?
SYNAPTOGENIX INC (SNPX) has a support level at 2.4 and a resistance level at 2.41. Check the full technical report for a detailed analysis of SNPX support and resistance levels.
Should I buy SYNAPTOGENIX INC (SNPX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SNPX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SNPX, evaluating the profitability, health, valuation and growth aspects
- SYNAPTOGENIX INC (SNPX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SYNAPTOGENIX INC (SNPX) Sales and EPS estimates to see what analysts future expectations are.
- SYNAPTOGENIX INC (SNPX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SYNAPTOGENIX INC (SNPX) Insider and Institutional Ownership to learn about the owners and their transactions.
- SYNAPTOGENIX INC (SNPX) Stock Chart to make your own analysis
- SYNAPTOGENIX INC (SNPX) Latest news and press-releases to stay up to date.
Does SYNAPTOGENIX INC (SNPX) stock pay dividends?
SNPX does not pay a dividend.
What is the Price/Earnings (PE) ratio of SYNAPTOGENIX INC (SNPX)?
SYNAPTOGENIX INC (SNPX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-51.75).
What is the Short Interest ratio of SYNAPTOGENIX INC (SNPX) stock?
The outstanding short interest for SYNAPTOGENIX INC (SNPX) is 0.11% of its float. Check the ownership tab for more information on the SNPX short interest.
SNPX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SNPX. When comparing the yearly performance of all stocks, SNPX is a bad performer in the overall market: 87.69% of all stocks are doing better.
SNPX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SNPX. No worries on liquidiy or solvency for SNPX as it has an excellent financial health rating, but there are worries on the profitability.
SNPX Financial Highlights
Over the last trailing twelve months SNPX reported a non-GAAP Earnings per Share(EPS) of -51.75. The EPS increased by 76.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -76.46% | ||
| ROE | -200.08% | ||
| Debt/Equity | 0 |
SNPX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to SNPX. The Buy consensus is the average rating of analysts ratings from 7 analysts.